Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|13|5|463-470

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.13, Iss.5, 2007-01, pp. : 463-470

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting signaling pathways in lung cancer therapy

By Cho William CS  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 2, 2013-02 ,pp. : 107-111

Informa Healthcare

Access to resources Recommend Favorite

Targeting signaling pathways in ovarian cancer

By Reibenwein J   Krainer M  

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 3, 2008-03 ,pp. : 353-365

Informa Healthcare

Access to resources Recommend Favorite

Antisense and therapeutic oligonucleotides: toward a gene-targeting cancer clinic

By Cho-Chung Y.S.  

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 11, 2000-11 ,pp. : 1711-1724

Informa Healthcare

Access to resources Recommend Favorite

Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides

By Dias N.   Stein C.A.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 54, Iss. 3, 2002-11 ,pp. : 263-269

Elsevier

Access to resources Recommend Favorite

Targeting Apoptosis Pathways in Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 4, Iss. 7, 2004-11 ,pp. : 569-576

Bentham Science Publishers

Access to resources Recommend Favorite